Business Context and Reporting Period
This Form 10-Q covers the fiscal quarter ended August 29, 2010, for Landec Corporation (Note: The input metadata references "LIFECORE BIOMEDICAL, INC.", but the filing text identifies the registrant as Landec Corporation, which acquired Lifecore Biomedical, Inc. on April 30, 2010). Landec operates in four segments: Food Products Technology (Apio), Export, HA-based Biomaterials (Lifecore), and Technology Licensing. The company designs, develops, and sells polymer products for food, agriculture, and medical devices.
Key Financial Metrics
| Metric | Q1 2011 (Ended Aug 29, 2010) | Q1 2010 (Ended Aug 30, 2009) |
|---|---|---|
| Total Revenues | $64,953,000 | $60,943,000 |
| Gross Profit | $11,817,000 | $8,870,000 |
| Gross Margin | 18.2% | 14.6% |
| Operating Income | $3,933,000 | $3,361,000 |
| Net Income (Applicable to Common Stockholders) | $2,304,000 | $2,184,000 |
| Diluted EPS | $0.09 | $0.08 |
| Cash and Cash Equivalents | $9,898,000 | $3,998,000 (End of prior period) |
| Marketable Securities | $40,736,000 | $20,421,000 (End of prior period) |
| Total Debt (Current + Long-term) | $23,155,000 | $23,770,000 (End of prior period) |
| Operating Cash Flow | $4,383,000 | $4,276,000 |
Material Changes vs. Prior Period
- Revenue Growth: Total revenues increased 7% year-over-year, driven primarily by the inclusion of the newly acquired Lifecore Biomedical (HA-based Biomaterials) segment, which contributed $6.385 million in revenue. The Food Products Technology segment saw a slight decline of 3% due to lower unit sales volumes.
- Profitability: Gross profit increased 33% to $11.8 million, largely due to the higher-margin HA-based Biomaterials business. Operating income rose 17% to $3.9 million.
- Expense Increases: Research and Development (R&D) expenses surged 138% to $2.2 million, and Selling, General, and Administrative (SG&A) expenses increased 24% to $5.7 million. Both increases are primarily attributable to the integration of Lifecore operations.
- Interest Expense: Interest expense increased significantly from $1,000 to $227,000 due to a new $20 million credit facility entered into to finance the Lifecore acquisition.
- Liquidity: Cash and cash equivalents decreased by $17.9 million during the quarter, primarily due to net purchases of marketable securities ($20.5 million) and capital expenditures ($1.7 million), partially offset by strong operating cash flow.
Guidance, Outlook, and Risks
- Acquisition Integration: The company is integrating Lifecore Biomedical, acquired on April 30, 2010, for a total consideration of approximately $49.65 million (including $40 million cash and up to $10 million in earn-out payments). The earn-out is contingent on Lifecore achieving specific revenue targets in 2011 and 2012.
- Debt Covenants: The company entered into a $20 million credit agreement with Wells Fargo. As of August 29, 2010, the company was in compliance with all financial covenants, though amendments were made in August and September 2010 to modify certain terms.
- Stock Repurchase: The Board approved a $10 million stock repurchase plan in July 2010. During the quarter, the company repurchased 66,000 shares for $362,000.
- Risks: The filing notes that results are not necessarily indicative of full-year results due to seasonality in the Apio food business. Key risks include the ability to meet earn-out targets for the Lifecore acquisition, compliance with debt covenants, and the success of commercializing new polymer technologies.
- Impairment: The company recorded a $1.0 million impairment loss on its investment in Aesthetic Sciences Corporation in the prior fiscal year; the carrying value as of August 29, 2010, was $792,000.
Investor Verification Checklist
- Lifecore Earn-Out Probability: Verify the likelihood of Lifecore achieving the revenue targets required to trigger the up to $10 million contingent payment.
- Debt Covenant Compliance: Monitor the company's ability to maintain the minimum net income, quick ratio, and fixed coverage ratio required by the Wells Fargo credit agreement.
- Customer Concentration: Note that the top five customers accounted for 42% of revenues, with Costco Wholesale Corp. alone representing 15% of total sales.
- Inventory Levels: Inventory increased by $1.96 million during the quarter; verify if this buildup aligns with seasonal demand or indicates potential obsolescence risks.
- Interest Rate Exposure: Confirm the status of the interest rate swap agreement (fixed at 4.24% on $20 million) and its impact on future interest expense.